News Roche's KRAS drug tops its rivals in lung cancer trial Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.
News Vertex gets paediatric FDA okay for Casgevy gene therapy For the first time, children in the US as young as two with blood disorders sickle cell disease and beta thalassaemia are eligible for gene therapy.
News Colorado's pathfinder medicine price-cap move stalls A federal judge in the US has sided with Amgen in a dispute over a price cap imposed by the state of Colorado on blockbuster immunology drug Enbrel.
News NICE guidance calls for quicker diagnosis of PMOS Women with polyendocrine metabolic ovarian syndrome (PMOS) should be diagnosed sooner and be offered an annual review, according to new NICE guidance.
News Ipsen's M&A team strikes again, adding Memo in $700m deal Ipsen will pay up to €700m to take control of Memo Therapeutics and its drug for BK polyomavirus, which can lead to the failure of kidney transplants.
News FDA clears Orca's cell therapy Tregzi for GvHD Orca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.